Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) Short Interest Update

Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 1,500 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is currently 5.0 days.

Jacobio Pharmaceuticals Group Price Performance

JBPHF stock remained flat at $0.72 during midday trading on Monday. Jacobio Pharmaceuticals Group has a 1-year low of $0.60 and a 1-year high of $0.74. The business’s fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.79.

Jacobio Pharmaceuticals Group Company Profile

Jacobio Pharmaceuticals Group is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancer. The company uses proprietary drug-discovery platforms to develop small-molecule medicines aimed at genetically defined or otherwise difficult-to-treat tumors.

Its pipeline has included JAB-21822, also known as glecirasib, an investigational KRAS G12C inhibitor designed to target cancers driven by KRAS G12C mutations. Jacobio has also developed JAB-3312, an SHP2 inhibitor intended for use in oncology, along with other early-stage programs involving targets such as BET proteins and additional cancer-related pathways.

Jacobio conducts research and clinical-development activities primarily in China, with programs and collaborations extending to international markets, including the United States.